Xenon Pharmaceuticals Inc. (NASDAQ:XENE) Stock Holdings Lowered by Thrivent Financial for Lutherans

Thrivent Financial for Lutherans reduced its holdings in shares of Xenon Pharmaceuticals Inc. (NASDAQ:XENE - Free Report) by 28.8% in the 4th quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 30,699 shares of the biopharmaceutical company's stock after selling 12,394 shares during the quarter. Thrivent Financial for Lutherans' holdings in Xenon Pharmaceuticals were worth $1,203,000 at the end of the most recent quarter.

Several other large investors also recently made changes to their positions in the business. Janus Henderson Group PLC boosted its position in Xenon Pharmaceuticals by 144.2% during the 3rd quarter. Janus Henderson Group PLC now owns 2,552,392 shares of the biopharmaceutical company's stock worth $100,506,000 after purchasing an additional 1,507,135 shares during the period. JPMorgan Chase & Co. boosted its position in shares of Xenon Pharmaceuticals by 1,263.2% in the third quarter. JPMorgan Chase & Co. now owns 976,783 shares of the biopharmaceutical company's stock worth $38,456,000 after buying an additional 905,129 shares during the period. Jennison Associates LLC grew its stake in shares of Xenon Pharmaceuticals by 39.0% in the fourth quarter. Jennison Associates LLC now owns 801,553 shares of the biopharmaceutical company's stock valued at $31,421,000 after buying an additional 224,892 shares in the last quarter. FMR LLC raised its holdings in shares of Xenon Pharmaceuticals by 2.2% during the 3rd quarter. FMR LLC now owns 6,917,684 shares of the biopharmaceutical company's stock valued at $272,349,000 after buying an additional 149,511 shares during the period. Finally, Walleye Capital LLC acquired a new position in Xenon Pharmaceuticals during the 3rd quarter worth approximately $4,132,000. Institutional investors and hedge funds own 95.45% of the company's stock.

Remove Ads

Analyst Upgrades and Downgrades

A number of research firms have recently issued reports on XENE. William Blair reiterated an "outperform" rating on shares of Xenon Pharmaceuticals in a research note on Friday, February 28th. Royal Bank of Canada reaffirmed an "outperform" rating on shares of Xenon Pharmaceuticals in a research note on Friday, February 28th. HC Wainwright reissued a "buy" rating and issued a $53.00 price objective on shares of Xenon Pharmaceuticals in a research report on Monday, February 24th. Deutsche Bank Aktiengesellschaft started coverage on Xenon Pharmaceuticals in a research report on Tuesday, February 11th. They set a "buy" rating and a $67.00 target price on the stock. Finally, StockNews.com raised Xenon Pharmaceuticals from a "sell" rating to a "hold" rating in a report on Saturday, March 29th. One equities research analyst has rated the stock with a hold rating and nine have given a buy rating to the company. According to data from MarketBeat.com, the company presently has an average rating of "Moderate Buy" and an average target price of $57.38.

Insider Activity at Xenon Pharmaceuticals

In other Xenon Pharmaceuticals news, CEO Ian Mortimer sold 16,315 shares of Xenon Pharmaceuticals stock in a transaction that occurred on Monday, January 27th. The stock was sold at an average price of $40.50, for a total value of $660,757.50. Following the completion of the transaction, the chief executive officer now directly owns 31,302 shares in the company, valued at $1,267,731. The trade was a 34.26 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available at this link. Insiders own 5.52% of the company's stock.

Xenon Pharmaceuticals Stock Down 4.3 %

Shares of XENE traded down $1.31 during mid-day trading on Friday, hitting $29.40. The stock had a trading volume of 728,349 shares, compared to its average volume of 406,359. Xenon Pharmaceuticals Inc. has a fifty-two week low of $29.20 and a fifty-two week high of $46.00. The company has a market cap of $2.25 billion, a PE ratio of -10.43 and a beta of 1.21. The company's fifty day simple moving average is $36.90 and its two-hundred day simple moving average is $39.43.

Xenon Pharmaceuticals (NASDAQ:XENE - Get Free Report) last released its quarterly earnings data on Thursday, February 27th. The biopharmaceutical company reported ($0.84) EPS for the quarter, topping analysts' consensus estimates of ($0.89) by $0.05. Equities analysts expect that Xenon Pharmaceuticals Inc. will post -3.1 earnings per share for the current year.

About Xenon Pharmaceuticals

Xenon Pharmaceuticals Inc, a neuroscience-focused biopharmaceutical company, engages in the development of therapeutics to treat patients with neurological disorders in Canada. Its clinical development pipeline includes XEN1101, a novel and potent Kv7 potassium channel opener, which is in Phase 3 clinical trials for the treatment of epilepsy and other neurological disorders.